Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. (SNDX) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · SNDX · as of Jun 9, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
12
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Syndax Pharmaceuticals, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
SNDX insider buying and selling by quarter
SNDX insider selling · SNDX insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · SNDX ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
SNDX executive sell shares · SNDX board member insider trading · SNDX insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 1, 2026 | Goldan Keith A. CFO | Sale | 1,177 | $22K | Form 4 |
| Jun 1, 2026 | Metzger Michael A CEO · Director | Sale | 6,847 | $130K | Form 4 |
| Feb 9, 2026 | Metzger Michael A CEO · Director | Sale | 17,159 | $361K | Form 4 |
| Feb 9, 2026 | Goldan Keith A. CFO | Sale | 3,410 | $72K | Form 4 |
| Feb 4, 2026 | Metzger Michael A CEO · Director | Award | 144,600 | — | Form 4 |
| Feb 6, 2026 | Metzger Michael A CEO · Director | Sale | 7,412 | $153K | Form 4 |
| Feb 4, 2026 | Metzger Michael A CEO · Director | Award | 73,000 | — | Form 4 |
| Feb 4, 2026 | Goldan Keith A. CFO | Award | 30,750 | — | Form 4 |
| Feb 6, 2026 | Goldan Keith A. CFO | Sale | 2,082 | $43K | Form 4 |
| Feb 4, 2026 | Goldan Keith A. CFO | Award | 21,500 | — | Form 4 |
| Jan 30, 2026 | Goldan Keith A. CFO | Other | 1,219 | $10K | Form 4 |
| Feb 4, 2026 | Jarrett Jennifer Director | Award | 24,000 | — | Form 4 |
| Feb 4, 2026 | Huber Martin H. Jr. Director | Award | 24,000 | — | Form 4 |
| Feb 4, 2026 | Botwood Nicholas A.J. Head of R&D, CMO | Award | 36,000 | — | Form 4 |
| Feb 4, 2026 | Botwood Nicholas A.J. Head of R&D, CMO | Award | 24,000 | — | Form 4 |
| Feb 4, 2026 | Podlesak Dennis Director | Award | 48,000 | — | Form 4 |
| Feb 4, 2026 | Rizo Aleksandra Director | Award | 24,000 | — | Form 4 |
| Feb 4, 2026 | Katkin Keith Director | Award | 24,000 | — | Form 4 |
| Feb 4, 2026 | Legault Pierre Director | Award | 24,000 | — | Form 4 |
| Dec 1, 2025 | Goldan Keith A. CFO | Gift | 1,224 | — | Form 4 |
| Sep 8, 2025 | Metzger Michael A CEO · Director | Option | 157,307 | $1.71M⚡ | Form 4 |
| Sep 8, 2025 | Metzger Michael A CEO · Director | Sale | 157,307 | $2.58M⚡ | Form 4 |
| Aug 18, 2025 | Podlesak Dennis Director | Option | 19,200 | $138K | Form 4 |
| Aug 18, 2025 | Podlesak Dennis Director | Sale | 19,200 | $304K | Form 4 |
| Aug 14, 2025 | Podlesak Dennis Director | Sale | 19,200 | $273K | Form 4 |
Metzger Michael A
CEO · Director
Date
Sep 8
Shares
157,307
Price
$10.90
Value
$1.71M ⚡
Metzger Michael A
CEO · Director
Date
Sep 8
Shares
157,307
Price
$16.41
Value
$2.58M ⚡
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About SNDX insider trading
SNDX insider trades
Syndax Pharmaceuticals, Inc. (SNDX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Goldan Keith A. (CFO), Metzger Michael A (CEO · Director), Podlesak Dennis (Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. SNDX insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Syndax Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
SNDX insider trading · 5 questionsThe insiders of Syndax Pharmaceuticals, Inc. (SNDX) include executives and directors such as Goldan Keith A. (CFO), Metzger Michael A (CEO · Director), Podlesak Dennis (Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026